239 related articles for article (PubMed ID: 24175836)
21. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
[TBL] [Abstract][Full Text] [Related]
22. Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma.
Yang Y; Xia T; Li N; Zhang J; Yang Y; Cong W; Deng Q; Lan K; Zhou W
Protein Cell; 2013 Jan; 4(1):71-81. PubMed ID: 23292895
[TBL] [Abstract][Full Text] [Related]
23. MDM2 SNP309 polymorphism is associated with colorectal cancer risk.
Wang W; Du M; Gu D; Zhu L; Chu H; Tong N; Zhang Z; Xu Z; Wang M
Sci Rep; 2014 May; 4():4851. PubMed ID: 24797837
[TBL] [Abstract][Full Text] [Related]
24. TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: evidence from an updated meta-analysis.
Peng Q; Lao X; Chen Z; Lai H; Deng Y; Wang J; Mo C; Sui J; Wu J; Zhai L; Yang S; Qin X; Li S
PLoS One; 2013; 8(12):e82773. PubMed ID: 24376578
[TBL] [Abstract][Full Text] [Related]
25. TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women.
Zając A; Smolarz B; Stachowiak G; Wilczyński JR
Med Oncol; 2014 Nov; 31(11):286. PubMed ID: 25316267
[TBL] [Abstract][Full Text] [Related]
26. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
Nan H; Qureshi AA; Hunter DJ; Han J
Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
[TBL] [Abstract][Full Text] [Related]
27. Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck.
Yu H; Huang YJ; Liu Z; Wang LE; Li G; Sturgis EM; Johnson DG; Wei Q
Mol Carcinog; 2011 Sep; 50(9):697-706. PubMed ID: 21656578
[TBL] [Abstract][Full Text] [Related]
28. MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib.
Liu YC; Hsiao HH; Yang WC; Liu TC; Chang CS; Yang MY; Lin PM; Hsu JF; Lee CP; Lin SF
Mol Carcinog; 2014 Dec; 53(12):951-9. PubMed ID: 23818300
[TBL] [Abstract][Full Text] [Related]
29. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
[TBL] [Abstract][Full Text] [Related]
30. Association between polymorphisms of TP53 and MDM2 and prostate cancer risk in southern Chinese.
Xu B; Xu Z; Cheng G; Min ZC; Mi Y; Zhang ZZ; Tao J; Li PC; Wang ML; Tang JL; Zhang ZD; Zhang W; Wu HF; Feng NH; Hua LX
Cancer Genet Cytogenet; 2010 Oct; 202(2):76-81. PubMed ID: 20875869
[TBL] [Abstract][Full Text] [Related]
31. Genetic variations in MDM2 and P53 genes confer risk for adult acute lymphoblastic leukemia in a Chinese population.
Chen J; Zhu B; Chen J; Li Y
DNA Cell Biol; 2013 Jul; 32(7):414-9. PubMed ID: 23745682
[TBL] [Abstract][Full Text] [Related]
32. MDM2 rs2279744 and TP53 rs1042522 polymorphisms associated with etoposide- and cisplatin-induced grade III/IV neutropenia in Chinese extensive-stage small-cell lung cancer patients.
Wang X; Wang YZ; Ma KW; Chen X; Li W
Oncol Res Treat; 2014; 37(4):176-80. PubMed ID: 24732641
[TBL] [Abstract][Full Text] [Related]
33. Effects of p53 codon 72 and MDM2 SNP309 polymorphisms on gastric cancer risk among the Iranian population.
Moradi MT; Salehi Z; Aminian K; Yazdanbod A
Asian Pac J Cancer Prev; 2014; 15(17):7413-7. PubMed ID: 25227851
[TBL] [Abstract][Full Text] [Related]
34. Lung cancer risk in relation to TP53 codon 47 and codon 72 polymorphism in Bangladeshi population.
Mostaid MS; Ahmed MU; Islam MS; Bin Sayeed MS; Hasnat A
Tumour Biol; 2014 Oct; 35(10):10309-17. PubMed ID: 25034526
[TBL] [Abstract][Full Text] [Related]
35. p53 Arg72Pro, MDM2 T309G and CCND1 G870A polymorphisms are not associated with susceptibility to esophageal adenocarcinoma.
Liu G; Cescon DW; Zhai R; Zhou W; Kulke MH; Ma C; Xu W; Su L; Asomaning K; Heist RS; Wain JC; Lynch TJ; Christiani DC
Dis Esophagus; 2010 Jan; 23(1):36-9. PubMed ID: 19302219
[TBL] [Abstract][Full Text] [Related]
36. Combined effects of MDM2 SNP309 and TP53 R72P polymorphisms, and soy isoflavones on breast cancer risk among Chinese women in Singapore.
Koh WP; Van Den Berg D; Jin A; Wang R; Yuan JM; Yu MC
Breast Cancer Res Treat; 2011 Dec; 130(3):1011-9. PubMed ID: 21833626
[TBL] [Abstract][Full Text] [Related]
37. Lack of association between MDM2 SNP309 and TP53 Arg72Pro polymorphisms with clinical outcomes in myelodysplastic syndrome.
Machado-Neto JA; Traina F; De Melo Campos P; Andreoli-Risso MF; Costa FF; Olalla Saad ST
Neoplasma; 2012; 59(5):530-5. PubMed ID: 22668018
[TBL] [Abstract][Full Text] [Related]
38. Association of MDM2 and p53 polymorphisms with the advancement of cervical carcinoma.
Singhal P; Hussain S; Thakur N; Batra S; Salhan S; Bhambani S; Bharadwaj M
DNA Cell Biol; 2013 Jan; 32(1):19-27. PubMed ID: 23210739
[TBL] [Abstract][Full Text] [Related]
39. Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma.
Renouf DJ; Zhai R; Sun B; Xu W; Cheung WY; Heist RS; Kulke MH; Cescon D; Asomaning K; Marshall AL; Li S; Christiani DC; Liu G
J Gastroenterol Hepatol; 2013 Sep; 28(9):1482-8. PubMed ID: 23735059
[TBL] [Abstract][Full Text] [Related]
40. Association of Murine Double Minute 2 Genotypes and Lung Cancer Risk.
Lin YC; Chang WS; Shen TC; Li HT; Li CH; Hsiau YC; Wang YC; Wu CN; Gong CL; Wang ZH; Tsai CW; Hsia TC; Bau DT
In Vivo; 2020; 34(3):1047-1052. PubMed ID: 32354891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
